Clinical Trial: NCT02545283 - My Cancer Genome

NCT02545283

Description:

This is a multicenter, double-blind, randomized, placebo-controlled study designed to compare overall survival in participants with relapsed or refractory AML treated with idasanutlin in combination with cytarabine versus participants treated with placebo and cytarabine. Participants will receive induction treatment with idasanutlin/placebo and cytarabine (Cycle 1). Responding participants may continue to receive a maximum of further two cycles of consolidation (Cycle 2 and Cycle 3). Complete remission (CR), CR with incomplete platelet count recovery (CRp), overall remission rate (ORR), event-free survival (EFS) and percentage of participants with an allogeneic hematopoietic stem cell transplant (HSCT) will also be compared between treatment arms. This study will include participants with and without TP53 wild type (TP53 WT) mutations.

Related Conditions:

Acute Myeloid Leukemia

Recruiting Status:

Terminated

Phase:

Phase 3

URL:

https://clinicaltrials.gov/show/NCT02545283

Trial Eligibility

Document

Title

Brief Title: A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial IDs

ORG STUDY ID: WO29519
SECONDARY ID: 2014-003065-15
NCT ID: NCT02545283

Conditions

Leukemia, Myeloid, Acute

Interventions

Drug	Synonyms	Arms
Cytarabine		Idasanutlin plus Cytarabine
Idasanutlin		Idasanutlin plus Cytarabine

Purpose

This is a multicenter, double-blind, randomized, placebo-controlled study designed to compare overall survival in participants with relapsed or refractory AML treated with idasanutlin in combination with cytarabine versus participants treated with placebo and cytarabine. Participants will receive induction treatment with idasanutlin/placebo and cytarabine (Cycle 1). Responding participants may continue to receive a maximum of further two cycles of consolidation (Cycle 2 and Cycle 3). Complete remission (CR), CR with incomplete platelet count recovery (CRp), overall remission rate (ORR), event-free survival (EFS), leukemia-free survival (LFS) and percentage of participants with an allogeneic hematopoietic stem cell transplant (HSCT) will also be compared between treatment arms. This study will include participants with and without TP53 wild type (TP53 WT) mutations.

Trial Arms

Name	Type	Description	Interventions
Idasanutlin plus Cytarabine	Experimental	Participants will receive induction therapy idasanutlin and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.	Cytarabine Idasanutlin
Placebo plus Cytarabine	Placebo Comparator	Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.	Cytarabine

Eligibility Criteria

        Inclusion Criteria:

          -  Documented/confirmed first/second refractory/relapsed AML using World Health
             Organization classification, except acute promyelocytic leukemia

          -  No more than 2 prior induction regimens (excluding prior HSCT) in their first line
             treatment and one must have included cytarabine with an anthracycline (or
             anthracenedione)

          -  Eastern Cooperative Oncology Group performance status of 0 to 1

          -  Adequate hepatic and renal function

          -  White blood cell (WBC) count at randomization less than or equal to (</=) 50000 cells
             per cubic millimeter (/mm^3)

        Exclusion Criteria:

          -  First relapsed participants aged less than (<) 60 years with first CR duration greater
             than (>) 1 year

          -  Participants with prior documented antecedent hematological disorder (AHD)

          -  AML secondary to any prior chemotherapy unrelated to leukemia

          -  Participants who are either refractory to or relapsed within 90 days of receiving a
             regimen containing a cumulative dose of greater than or equal to (>/=) 18 g/m^2 of
             cytarabine

          -  Participants who have received allogeneic HSCT within 90 days prior to randomization

          -  Participants who have received immunosuppressive therapy for graft versus host disease
             within 2 weeks prior to randomization

          -  Prior treatment with an Murine Double Minute 2 (MDM2) antagonist

          -  Participants receiving any other investigational or commercial agents or therapies
             administered with the intention to treat their malignancy within 30 days from first
             receipt of study drug

          -  Participants with a history of other malignancy within 5 years prior to screening

          -  Participants who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

          -  Participants with extramedullary AML with no evidence of systemic involvement

          -  Pregnant or breastfeeding participants

Maximum Eligible Age:	N/A
Minimum Eligible Age:	18 Years
Eligible Gender:	All
Healthy Volunteers:	No

Primary Outcome Measures

Measure:	Overall Survival in TP53 WT Population
Time Frame:	Baseline up to approximately 3.5 years
Safety Issue:
Description:

Secondary Outcome Measures

Measure:	Overall Survival in the Overall Population
Time Frame:	Baseline up to approximately 3.5 years
Safety Issue:
Description:

Measure:	Percentage of Participants in CR at the End of Induction According to Hematologic Malignancy Response Assessment (HMRA) in TP53 WT Population
Time Frame:	At the end of induction (up to Day 56)
Safety Issue:
Description:

Measure:	Percentage of Participants in CRp at the End of Induction According to HMRA in TP53 WT Population
Time Frame:	At the end of induction (up to Day 56)
Safety Issue:
Description:

Measure:	Percentage of Participants with Overall Remission at the End of Induction According to HMRA in TP53 WT Population
Time Frame:	At the end of induction (up to Day 56)
Safety Issue:
Description:

Measure:	EFS According to HMRA in TP53 WT Population
Time Frame:	Baseline up to treatment failure, relapse or death from any cause (up to approximately 3.5 years)
Safety Issue:
Description:

Measure:	LFS According to HMRA in TP53 WT Population
Time Frame:	Date of remission to date of relapse or death (up to approximately 3.5 years)
Safety Issue:
Description:

Measure:	Percentage of Participants Undergoing HSCT Following Response, in TP53 WT Population
Time Frame:	Baseline up to approximately 3.5 years
Safety Issue:
Description:

Measure:	Percentage of Participants in CR at the End of Induction According to HMRA in Overall Population
Time Frame:	At the end of induction (up to Day 56)
Safety Issue:
Description:

Measure:	Percentage of Participants in CRp at the End of Induction According to HMRA in Overall Population
Time Frame:	At the end of induction (up to Day 56)
Safety Issue:
Description:

Measure:	Percentage of Participants with Overall Remission at the End of Infusion According to HMRA in Overall Population
Time Frame:	At the end of induction (up to Day 56)
Safety Issue:
Description:

Measure:	EFS According to HMRA in Overall Population
Time Frame:	Baseline up to treatment failure, relapse or death from any cause (up to approximately 3.5 years)
Safety Issue:
Description:

Measure:	LFS According to HMRA in Overall Population
Time Frame:	Date of remission to date of relapse or death (up to approximately 3.5 years)
Safety Issue:
Description:

Measure:	Percentage of Participants Undergoing HSCT Following Response, in Overall Population
Time Frame:	Baseline up to approximately 3.5 years
Safety Issue:
Description:

Measure:	Apparent Clearance (CL/F) of Idasanutlin
Time Frame:	Cycle 1: Predose (0 hour [Hr]), end of 1-3 Hr cytarabine infusion, 6 Hr postdose on Days 1, 5; Predose (0 Hr) on Day 2; at Days 8, 10; Cycle 2, 3: predose (0 Hr) on Days 2, 5 (predose/postdose: relative to idasanutlin morning dose; cycle length= 28 days)
Safety Issue:
Description:

Measure:	Apparent Volume of Distribution (Vd/F) of Idasanutlin
Time Frame:	Cycle 1: Predose (0 Hr), end of 1-3 Hr cytarabine infusion, 6 Hr postdose on Days 1, 5; Predose (0 Hr) on Day 2; at Days 8, 10; Cycle 2, 3: predose (0 Hr) on Days 2, 5 (predose/postdose: relative to idasanutlin morning dose; cycle length= 28 days)
Safety Issue:
Description:

Measure:	Maximum Concentration Observed (Cmax) of Idasanutlin
Time Frame:	Cycle 1: Predose (0 Hr), end of 1-3 Hr cytarabine infusion, 6 Hr postdose on Days 1, 5; Predose (0 Hr) on Day 2; at Days 8, 10; Cycle 2, 3: predose (0 Hr) on Days 2, 5 (predose/postdose: relative to idasanutlin morning dose; cycle length= 28 days)
Safety Issue:
Description:

Measure:	Steady-State Concentration (C trough) of Idasanutlin
Time Frame:	Cycle 1: Predose (0 Hr), end of 1-3 Hr cytarabine infusion, 6 Hr postdose on Days 1, 5; Predose (0 Hr) on Day 2; at Days 8, 10; Cycle 2, 3: predose (0 Hr) on Days 2, 5 (predose/postdose: relative to idasanutlin morning dose; cycle length= 28 days)
Safety Issue:
Description:

Measure:	Area Under the Concentration-Time Curve (AUC) During One Dosing Interval (AUCtau) of Idasanutlin
Time Frame:	Cycle 1: Predose (0 Hr), end of 1-3 Hr cytarabine infusion, 6 Hr postdose on Days 1, 5; Predose (0 Hr) on Day 2; at Days 8, 10; Cycle 2, 3: predose (0 Hr) on Days 2, 5 (predose/postdose: relative to idasanutlin morning dose; cycle length= 28 days)
Safety Issue:
Description:

Measure:	AUC from Time Zero to 24 Hours Post Dose (AUC0-24) of Idasanutlin
Time Frame:	Cycle 1: Predose (0 Hr), end of 1-3 Hr cytarabine infusion, 6 Hr postdose on Days 1, 5; Predose (0 Hr) on Day 2; at Days 8, 10; Cycle 2, 3: predose (0 Hr) on Days 2, 5 (predose/postdose: relative to idasanutlin morning dose; cycle length= 28 days)
Safety Issue:
Description:

Measure:	Half-Life (t 1/2) of Idasanutlin
Time Frame:	Cycle 1: Predose (0 Hr), end of 1-3 Hr cytarabine infusion, 6 Hr postdose on Days 1, 5; Predose (0 Hr) on Day 2; at Days 8, 10; Cycle 2, 3: predose (0 Hr) on Days 2, 5 (predose/postdose: relative to idasanutlin morning dose; cycle length= 28 days)
Safety Issue:
Description:

Measure:	Total Clearance (CL) of Cytarabine
Time Frame:	Cycle 1: Within 2 Hr pre-cytarabine dose, end of 1-3 Hr cytarabine infusion, 6 Hr post idasanutlin morning dose on Days 1, 5; Within 2 Hr pre-cytarabine dose on Day 2; Cycle 2, 3: Within 2 Hr pre-cytarabine dose on Day 2 (Cycle length= 28 days)
Safety Issue:
Description:

Measure:	Volume of Distribution (Vd) of Cytarabine
Time Frame:	Cycle 1: Within 2 Hr pre-cytarabine dose, end of 1-3 Hr cytarabine infusion, 6 Hr post idasanutlin morning dose on Days 1, 5; Within 2 Hr pre-cytarabine dose on Day 2; Cycle 2, 3: Within 2 Hr pre-cytarabine dose on Day 2 (Cycle length= 28 days)
Safety Issue:
Description:

Measure:	Percentage of Participants with Adverse Events
Time Frame:	Baseline up to approximately 3.5 years
Safety Issue:
Description:

Measure:	Change from Baseline in European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score
Time Frame:	Cycle 1 Day 1 (Baseline), Days 8, 15, 28 of Cycle 1, Days 1, 8, 15, 28 of Cycles 2, 3, 28 days after last dose (last dose on Cycle 3 Day 5), thereafter every 3 months until relapse (maximum up to 3.5 years)
Safety Issue:
Description:

Measure:	Change from Baseline in EuroQol 5 Dimension 5-Level (EQ-5D-5L) Questionnaire Score
Time Frame:	Cycle 1 Day 1 (Baseline), Days 8, 15, 28 of Cycle 1, Days 1, 8, 15, 28 of Cycles 2, 3, 28 days after last dose (last dose on Cycle 3 Day 5), thereafter every 3 months until relapse (maximum up to 3.5 years)
Safety Issue:
Description:

Details

Phase:	Phase 3
Primary Purpose:	Interventional
Overall Status:	Recruiting
Lead Sponsor:	Hoffmann-La Roche

Clinical Trials /

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)